SW
Summit Wealth Group, LLC
13F filer · CIK 0001802865Reported Aug 4, 2026
Net seller this quarter
13F portfolio value$490MU.S. long equity reported on 13F
Positions605 new · 5 closed
Net flow last quarter-$1.37MBuys minus sells
Top 10 positions weight8.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 4, 202660 positions | |||||
| $11.8M | 2.40% | Not reported | Not reported | Q1 2024 | |
| $5.38M | 1.10% | 0.00% | -1.0% | Q4 2019 | |
| $4.71M | 0.96% | 0.00% | +30.4% | Q1 2023 | |
| $4.43M | 0.90% | Not reported | -8.0% | Q3 2021 | |
| $4.06M | 0.83% | 0.01% | Not reported | Q1 2026 | |
| $3.92M | 0.80% | 0.00% | Not reported | Q1 2023 | |
| $3.71M | 0.76% | 0.00% | -31.3% | Q1 2021 | |
| $2.64M | 0.54% | 0.00% | -4.9% | Q4 2019 | |
| ETESPREsperion Therapeutics, Inc. | $1.58M | 0.32% | 0.19% | +23.3% | Q3 2024 |
| $1.55M | 0.32% | 0.00% | -3.8% | Q4 2019 | |
| $1.25M | 0.26% | Not reported | -8.0% | Q4 2020 | |
| $1.21M | 0.25% | 0.00% | -2.3% | Q1 2021 | |
| $1.03M | 0.21% | Not reported | +3.2% | Q4 2020 | |
| $1M | 0.20% | 0.00% | -10.4% | Q4 2019 | |
| $939K | 0.19% | 0.00% | 0.0% | Q4 2019 | |
| $856K | 0.17% | Not reported | +3.0% | Q1 2023 | |
| $723K | 0.15% | 0.00% | -2.8% | Q4 2019 | |
| $704K | 0.14% | 0.00% | Not reported | Q1 2023 | |
| $678K | 0.14% | 0.00% | -2.1% | Q1 2023 | |
| $662K | 0.13% | 0.00% | Not reported | Q1 2023 | |
| $629K | 0.13% | 0.00% | +8.6% | Q1 2021 | |
| $623K | 0.13% | 0.00% | -0.7% | Q4 2019 | |
| $585K | 0.12% | 0.00% | -0.6% | Q1 2023 | |
| $553K | 0.11% | 0.00% | +0.1% | Q1 2021 | |
| $551K | 0.11% | 0.00% | +3.9% | Q1 2021 | |
| $545K | 0.11% | 0.00% | -0.7% | Q2 2024 | |
| $531K | 0.11% | 0.07% | +0.3% | Q4 2019 | |
| $518K | 0.11% | 0.00% | -5.6% | Q1 2021 | |
| $516K | 0.11% | 0.00% | +9.7% | Q4 2019 | |
| $504K | 0.10% | Not reported | -4.6% | Q2 2020 | |
| $492K | 0.10% | 0.00% | Not reported | Q2 2025 | |
| $482K | 0.10% | 0.00% | -0.6% | Q1 2023 | |
| $466K | 0.10% | 0.00% | Not reported | Q4 2019 | |
| $425K | 0.09% | 0.00% | -13.5% | Q1 2023 | |
| $423K | 0.09% | 0.00% | -8.3% | Q3 2021 | |
| $411K | 0.08% | 0.00% | -9.2% | Q4 2020 | |
| $385K | 0.08% | 0.00% | Not reported | Q3 2025 | |
| $371K | 0.08% | 0.00% | -3.2% | Q1 2026 | |
| $359K | 0.07% | 0.00% | +0.3% | Q4 2019 | |
| $357K | 0.07% | Not reported | +26.5% | Q1 2021 | |
| $324K | 0.07% | 0.04% | Not reported | Q4 2025 | |
| $322K | 0.07% | 0.00% | +1.2% | Q1 2021 | |
| $320K | 0.07% | 0.00% | +0.1% | Q1 2023 | |
| $314K | 0.06% | 0.00% | Not reported | Q4 2023 | |
| $299K | 0.06% | 0.00% | Not reported | Q1 2023 | |
| $289K | 0.06% | 0.00% | -16.2% | Q1 2021 | |
| $288K | 0.06% | 0.00% | -1.7% | Q1 2023 | |
| $282K | 0.06% | 0.00% | +4.1% | Q1 2021 | |
| $275K | 0.06% | 0.00% | Not reported | Q4 2019 | |
| $272K | 0.06% | 0.00% | -16.9% | Q1 2021 | |
| Q1 2026Reported May 4, 202660 positions | |||||
| $11.1M | 2.55% | Not reported | -0.1% | Q1 2024 | |
| $4.76M | 1.09% | 0.00% | -3.8% | Q4 2019 | |
| $4.71M | 1.08% | 0.00% | +6.6% | Q1 2021 | |
| $4.44M | 1.02% | Not reported | -3.7% | Q3 2021 | |
| $3.14M | 0.72% | 0.00% | Not reported | Q1 2023 | |
| $2.76M | 0.63% | 0.00% | +10.8% | Q4 2019 | |
| $2.45M | 0.56% | 0.01% | New | Q1 2026 | |
| $1.41M | 0.32% | 0.00% | +18.2% | Q4 2019 | |
| ETESPREsperion Therapeutics, Inc. | $1.11M | 0.25% | 0.16% | +19.0% | Q3 2024 |
| $1.1M | 0.25% | 0.00% | -1.3% | Q4 2019 | |
| $1.06M | 0.24% | 0.00% | +0.9% | Q1 2023 | |
| $999K | 0.23% | 0.00% | +10.7% | Q1 2021 | |
| $969K | 0.22% | Not reported | -13.0% | Q4 2020 | |
| $843K | 0.19% | 0.00% | -3.1% | Q4 2019 | |
| $807K | 0.19% | Not reported | +1.4% | Q4 2020 | |
| $779K | 0.18% | Not reported | Not reported | Q1 2023 | |
| $658K | 0.15% | 0.00% | -1.3% | Q1 2021 | |
| $612K | 0.14% | 0.00% | +6.6% | Q1 2023 | |
| $585K | 0.13% | 0.00% | +0.1% | Q4 2019 | |
| $565K | 0.13% | 0.00% | +20.9% | Q4 2020 | |
| $537K | 0.12% | Not reported | +31.7% | Q2 2020 | |
| $535K | 0.12% | 0.00% | -2.1% | Q1 2023 | |
| $533K | 0.12% | 0.07% | +0.4% | Q4 2019 | |
| $521K | 0.12% | 0.00% | Not reported | Q1 2023 | |
| $517K | 0.12% | 0.00% | -1.5% | Q1 2021 | |
| $495K | 0.11% | 0.00% | +0.3% | Q2 2024 | |
| $493K | 0.11% | 0.00% | Not reported | Q1 2023 | |
| $490K | 0.11% | 0.00% | Not reported | Q4 2019 | |
| $484K | 0.11% | 0.00% | +8.8% | Q4 2019 | |
| $475K | 0.11% | 0.00% | -2.5% | Q1 2021 | |
| $453K | 0.10% | 0.00% | -1.4% | Q4 2019 | |
| $367K | 0.08% | 0.00% | -4.9% | Q1 2023 | |
| $366K | 0.08% | 0.00% | -2.6% | Q2 2025 | |
| $362K | 0.08% | 0.00% | -6.1% | Q1 2021 | |
| $354K | 0.08% | 0.00% | +15.6% | Q3 2021 | |
| $351K | 0.08% | 0.01% | +0.7% | Q2 2024 | |
| $351K | 0.08% | 0.00% | Not reported | Q3 2025 | |
| $347K | 0.08% | 0.00% | +0.2% | Q1 2023 | |
| $340K | 0.08% | 0.00% | +0.3% | Q4 2019 | |
| $327K | 0.07% | 0.00% | Not reported | Q1 2023 | |
| $323K | 0.07% | 0.03% | Not reported | Q4 2025 | |
| $319K | 0.07% | 0.00% | Not reported | Q1 2021 | |
| $319K | 0.07% | 0.00% | +64.0% | Q1 2021 | |
| $303K | 0.07% | 0.00% | +65.4% | Q1 2021 | |
| $291K | 0.07% | 0.00% | -0.1% | Q1 2021 | |
| $278K | 0.06% | 0.00% | Not reported | Q1 2023 | |
| $271K | 0.06% | 0.00% | New | Q1 2026 | |
| $258K | 0.06% | 0.00% | -2.1% | Q1 2023 | |
| $251K | 0.06% | Not reported | Not reported | Q1 2021 | |
| $246K | 0.06% | Not reported | Not reported | Q1 2021 | |
| Q4 2025Reported Feb 6, 202652 positions | |||||
| $11.9M | 2.77% | Not reported | Not reported | Q1 2024 | |
| $5.31M | 1.24% | 0.00% | +3.0% | Q4 2019 | |
| $4.73M | 1.10% | 0.00% | +7.8% | Q1 2021 | |
| $4.44M | 1.04% | Not reported | -1.4% | Q3 2021 | |
| $3.25M | 0.76% | 0.00% | +4.5% | Q4 2019 | |
| $1.32M | 0.31% | 0.00% | +9.5% | Q4 2019 | |
| ETESPREsperion Therapeutics, Inc. | $1.26M | 0.29% | 0.14% | +5.5% | Q3 2024 |
| $1.11M | 0.26% | 0.00% | +2.3% | Q4 2019 | |
| $1.07M | 0.25% | Not reported | -1.2% | Q4 2020 | |
| $983K | 0.23% | 0.00% | +13.8% | Q1 2021 | |
| $953K | 0.22% | 0.00% | +7.5% | Q4 2019 | |
| $884K | 0.21% | 0.00% | +3.1% | Q1 2023 | |
| $871K | 0.20% | Not reported | -3.7% | Q4 2020 | |
| $755K | 0.18% | Not reported | Not reported | Q1 2023 | |
| $694K | 0.16% | 0.00% | +10.9% | Q1 2023 | |
| $611K | 0.14% | 0.00% | +0.1% | Q4 2019 | |
| $593K | 0.14% | 0.00% | +5.8% | Q1 2023 | |
| $562K | 0.13% | 0.00% | +6.0% | Q1 2023 | |
| $545K | 0.13% | 0.00% | +23.2% | Q1 2021 | |
| $543K | 0.13% | 0.00% | Not reported | Q4 2019 | |
| $533K | 0.12% | 0.07% | -11.4% | Q4 2019 | |
| $511K | 0.12% | 0.00% | +0.2% | Q2 2024 | |
| $482K | 0.11% | 0.00% | Not reported | Q4 2019 | |
| $473K | 0.11% | 0.00% | +2.5% | Q1 2021 | |
| $470K | 0.11% | Not reported | +30.9% | Q2 2020 | |
| $469K | 0.11% | 0.00% | +4.6% | Q1 2023 | |
| $460K | 0.11% | 0.00% | +11.2% | Q1 2021 | |
| $423K | 0.10% | 0.00% | +8.0% | Q1 2021 | |
| $415K | 0.10% | 0.01% | +0.6% | Q2 2024 | |
| $389K | 0.09% | 0.00% | +8.3% | Q4 2019 | |
| $383K | 0.09% | 0.00% | +21.2% | Q1 2021 | |
| $358K | 0.08% | 0.00% | Not reported | Q3 2021 | |
| $357K | 0.08% | 0.00% | Not reported | Q1 2023 | |
| $353K | 0.08% | 0.00% | +1.7% | Q3 2025 | |
| $344K | 0.08% | 0.00% | +2.8% | Q4 2020 | |
| $322K | 0.08% | 0.00% | +7.1% | Q1 2023 | |
| $322K | 0.08% | 0.00% | +0.3% | Q4 2019 | |
| $318K | 0.07% | 0.00% | Not reported | Q4 2023 | |
| $304K | 0.07% | 0.03% | New | Q4 2025 | |
| $281K | 0.07% | 0.00% | +5.7% | Q2 2025 | |
| $278K | 0.06% | 0.00% | +0.2% | Q1 2023 | |
| $264K | 0.06% | 0.00% | +3.6% | Q1 2023 | |
| $258K | 0.06% | Not reported | -8.7% | Q1 2021 | |
| $250K | 0.06% | 0.00% | +9.1% | Q1 2023 | |
| $228K | 0.05% | 0.00% | Not reported | Q1 2021 | |
| $222K | 0.05% | 0.00% | Not reported | Q1 2021 | |
| $213K | 0.05% | 0.00% | Not reported | Q1 2021 | |
| $209K | 0.05% | 0.00% | +0.4% | Q1 2023 | |
| $207K | 0.05% | 0.00% | Not reported | Q1 2021 | |
| $203K | 0.05% | 0.00% | +2.8% | Q3 2021 | |
| Q3 2025Reported Oct 23, 202549 positions | |||||
| $11.4M | 2.77% | Not reported | 0.0% | Q1 2024 | |
| $4.83M | 1.17% | 0.00% | -0.9% | Q4 2019 | |
| $4.39M | 1.06% | 0.00% | Not reported | Q1 2021 | |
| $4.32M | 1.04% | Not reported | -2.1% | Q3 2021 | |
| $3.33M | 0.81% | 0.00% | -3.3% | Q4 2019 | |
| $1.16M | 0.28% | 0.00% | -0.2% | Q4 2019 | |
| $1.15M | 0.28% | 0.00% | -1.1% | Q4 2019 | |
| $992K | 0.24% | Not reported | -48.0% | Q4 2020 | |
| $868K | 0.21% | 0.00% | -1.1% | Q4 2019 | |
| ETESPREsperion Therapeutics, Inc. | $856K | 0.21% | 0.16% | Not reported | Q3 2024 |
| $742K | 0.18% | Not reported | Not reported | Q1 2023 | |
| $719K | 0.17% | 0.00% | -1.7% | Q4 2019 | |
| $702K | 0.17% | Not reported | -5.3% | Q4 2020 | |
| $670K | 0.16% | 0.00% | +0.2% | Q1 2021 | |
| $619K | 0.15% | 0.00% | -0.5% | Q1 2023 | |
| $603K | 0.15% | 0.08% | +0.6% | Q4 2019 | |
| $568K | 0.14% | 0.00% | Not reported | Q4 2019 | |
| $565K | 0.14% | 0.00% | Not reported | Q1 2021 | |
| $548K | 0.13% | 0.00% | -1.5% | Q1 2023 | |
| $503K | 0.12% | 0.00% | Not reported | Q1 2023 | |
| $501K | 0.12% | 0.00% | Not reported | Q4 2019 | |
| $475K | 0.11% | 0.00% | Not reported | Q1 2023 | |
| $449K | 0.11% | 0.00% | +0.3% | Q2 2024 | |
| $433K | 0.10% | 0.01% | +0.6% | Q2 2024 | |
| $432K | 0.10% | 0.00% | -4.2% | Q1 2021 | |
| $422K | 0.10% | 0.00% | +0.3% | Q1 2021 | |
| $409K | 0.10% | 0.00% | Not reported | Q1 2023 | |
| $402K | 0.10% | 0.00% | Not reported | Q4 2023 | |
| $400K | 0.10% | Not reported | Not reported | Q2 2020 | |
| $361K | 0.09% | 0.00% | New | Q3 2025 | |
| $349K | 0.08% | 0.00% | +0.1% | Q1 2023 | |
| $341K | 0.08% | 0.00% | Not reported | Q4 2020 | |
| $337K | 0.08% | 0.00% | +0.3% | Q4 2019 | |
| $329K | 0.08% | 0.00% | -1.4% | Q1 2021 | |
| $322K | 0.08% | 0.00% | -0.9% | Q4 2019 | |
| $286K | 0.07% | 0.00% | -0.6% | Q1 2023 | |
| $286K | 0.07% | 0.00% | +0.2% | Q1 2023 | |
| $281K | 0.07% | 0.00% | -2.8% | Q1 2021 | |
| PBPVBCProvident Bancorp, Inc. | $278K | 0.07% | 0.12% | -11.0% | Q2 2025 |
| $276K | 0.07% | Not reported | -2.4% | Q1 2021 | |
| $254K | 0.06% | 0.00% | Not reported | Q3 2021 | |
| $250K | 0.06% | 0.00% | -1.5% | Q2 2025 | |
| $226K | 0.05% | 0.00% | Not reported | Q1 2021 | |
| $225K | 0.05% | 0.00% | -4.3% | Q1 2023 | |
| $215K | 0.05% | 0.00% | -9.0% | Q1 2023 | |
| $212K | 0.05% | 0.00% | -45.2% | Q1 2023 | |
| $202K | 0.05% | 0.00% | Not reported | Q4 2020 | |
| $202K | 0.05% | 0.00% | -12.6% | Q3 2021 | |
| $76.9K | 0.02% | 0.00% | New | Q3 2025 | |
Premium opens every quarter this fund has filed